Bone Metastasis Market Research Report - Forecast to 2027

Global Bone Metastasis Market Research Report, by Type (Osteolytic, Osteoblastic, Mixed), Diagnosis (Biopsy, Blood Test, Imaging), Treatment (Medical Therapies, Surgery, Medication), End User (Hospital, Diagnostic Centers) - Global Forecast Till 2027

ID: MRFR/Pharma/4321-HCR | February 2021 | Region: Global | 90 pages

Please note that the assessment period of the report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


Bone metastasis is characterized by the spreading of cancerous cells from their original site to a bone. All types of cancer can show bone-metastasis. However, it is estimated that breast cancer and prostate cancer are commonly associated with the disease. The medical condition is frequent for spine, pelvis, and thighs. Urinary incontinence, bowel incontinence, and hypercalcemia are some of the common symptoms of the disease. The increasing prevalence of bone metastasis is expected to be a major driver for the market growth during the forecast period. According to a study published in the Oncology Reviews Journal in 2017, the relative occurrence of bone metastasis was estimated to be around 65 to 75% for both breast and prostate cancers suffering patients, respectively. Moreover, the growing geriatric population, increasing healthcare expenditures, and increasing R&D in the market are estimated to drive the market growth during the forecast period. According to the American Society of Clinical Oncology in 2016, approximately 60% of the total cancer patients aged 65 years or more. However, factors such as lack of healthcare services in low-income countries, the high cost of treatment, and related side effects are estimated to restrain the market growth during the forecast period. According to a study published in the Journal of Spine Surgery in 2017, the mean total cost of therapeutic modalities such as vertebroplasty was estimated to be about USD 14,114 in 2014.


The global bone metastasis market is expected to grow at an approximate CAGR of 8.4% during the forecast period 


Intended Audience



  • Pharmaceutical Companies

  • Biotechnological Institutes

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers


Figure 1: - Global Bone Metastasis Market Share, by Region


 Bone Metastasis Market Share


Sources: WHO, Oncology Reviews, American Society of Clinical Oncology, Cancer Research U.K., Journal of Spine Surgery, Annual Reports, Press Release, White Paper, and Company Presentation


Segmentation


The global bone metastasis market is segmented on the basis of type, diagnosis, treatment, and end-user.


On the basis of type, the market is segmented into osteolytic bone metastasis, osteoblastic bone metastasis, mixed bone metastasis, and others.


On the basis of diagnosis, the market is categorized into biopsy, blood test, imaging, and others. The imaging segment is sub-segmented into X-ray, bone scintigraphy, computerized tomography, magnetic resonance imaging, positron emission tomography, and others.


On the basis of the treatment, the market is segmented into medical therapies, surgery, medication, and others. The medical therapies segment is sub-segmented into chemotherapy, targeted therapy, hormone therapy, ablation therapy, and others. The ablation therapy segment is further segmented into radiofrequency ablation, cryoablation, and others. The surgery segment is sub-segmented into vertebroplasty, kyphoplasty, and others. The medication segment is sub-segmented into pain medications, bone building medications, and others. The pain medication segment is sub-segmented into ibuprofen, morphine, and others. The bone-building medications segment is sub-segmented into corticosteroids, bisphosphonates, and others. The bisphosphonates segment is further segmented into teriparatide, pamidronate, medronate, and others.


On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, pharmacies, and ambulatory surgical centers. Research Methodology


Methodology


Sources: WHO, Oncology Reviews, American Society of Clinical Oncology, Cancer Research U.K., Journal of Spine Surgery, Annual Reports, Press Release, White Paper, and Company Presentation


Regional Analysis


America dominates the global bone metastasis market. This can be attributed to the presence of a well-developed healthcare sector, the increasing prevalence of breast cancer, and increasing healthcare sector within the region. Moreover, the presence of key players such as Merck & Co., Inc. and Pfizer Inc. within the Americas boosts the regional market growth.


Europe is the second in the global bone metastasis market owing to the availability of funds for research and a huge patient population. According to the Cancer Research U.K., approximately 55,122 new cases of invasive breast cancer were reported in 2015. On a regional basis, Europe is segmented into Western Europe and Eastern Europe. Western Europe leads the regional market due to the presence of developed economies within the region.


Asia Pacific is projected to be the fastest growing region in the global bone metastasis market. The presence of developing economies such as India and China, a developing healthcare sector, and the growing prevalence of cancer within the region drive the market growth in the region. Moreover, favorable government policies and increasing penetration of key market players within the region fuel the market growth.


The Middle East and Africa holds the least share in the global bone metastasis market, owing to the presence of poor economies, stringent government policies, and lack of healthcare services, especially within the African region. A majority of the market of bone metastasis in the Middle East and Africa is held by the Middle East due to the presence of a well-developed healthcare sector and huge healthcare expenditure by developed economies such as Saudi Arabia, Kuwait, Dubai, and others within the region. Key players


The key players in the global bone metastasis market are F. Hoffmann-La Roche Ltd (Switzerland)


Bayer AG (Germany), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Pharmalucence Inc. (England), Koninklijke Philips N.V. (the Netherlands), GENERAL ELECTRIC (U.S.), Siemens AG (Germany), TOSHIBA CORPORATION (Japan), and others.



Frequently Asked Questions (FAQ) :


Bone metastasis is the condition when cancerous cells from other sites migrate to a bone.

Market is expected to exhibit a strong 8.4% CAGR over the forecast period till 2027.

Increasing prevalence of cancer is likely to be a major driver for the Bone Metastasis Market.

Americas hold the largest share in the Bone Metastasis Market.

Leading players in the Bone Metastasis Market include Merck, Bayer, and Pfizer, among others.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Bone Metastasis Market, by Type

6.1 Introduction

6.2 Osteolytic Bone Metastasis

Market Estimates & Forecast, 2020–2027

6.3 Osteoblastic Bone Metastasis

Market Estimates & Forecast, 2020–2027

6.4 Mixed Bone Metastasis

Market Estimates & Forecast, 2020–2027

6.5 Others

Chapter 7. Global Bone Metastasis Market, by Diagnosis

7.1 Introduction

7.2 Biopsy

Market Estimates & Forecast, 2020–2027

7.3 Blood Test

Market Estimates & Forecast, 2020–2027

7.4 Imaging

Market Estimates & Forecast, 2020–2027

7.4.1 X-ray

7.4.2 Bone Scintigraphy

7.4.3 Computerized Tomography

7.4.4 Magnetic Resonance Imaging

7.4.5 Positron Emission Tomography

7.4.6 Others

7.5 Others

Chapter 8. Global Bone Metastasis Market, by Treatment

8.1 Introduction

8.2 Medical Therapies

Market Estimates & Forecast, 2020–2027

8.2.1 Chemotherapy

8.2.2 Targeted therapy

8.2.3 Hormone therapy

8.2.4 Ablation Therapy

Market Estimates & Forecast, 2020–2027

8.2.4.1 Radiofrequency Ablation

8.2.4.2 Cryoablation

8.2.4.3 Others

8.2.5 Others

8.3 Surgery

Market Estimates & Forecast, 2020–2027

8.3.1 Vertebroplasty

8.3.2 Kyphoplasty

8.4 Medication

Market Estimates & Forecast, 2020–2027

8.4.1 Pain Medications

Market Estimates & Forecast, 2020–2027

8.4.1.1 Ibuprofen

8.4.1.2 Morphine

8.4.1.3 Others

8.4.2 Bone-Building Medications

Market Estimates & Forecast, 2020–2027

8.4.2.1 Corticosteroids

8.4.2.2 Bisphosphonates

Market Estimates & Forecast, 2020–2027

8.4.2.2.1 Teriparatide

8.4.2.2.2 Pamidronate

8.4.2.2.3 Medronate

8.5 Others

Chapter 9. Global Bone Metastasis Market, by End-User

9.1 Introduction

9.2 Hospital & Clinics

Market Estimates & Forecast, 2020–2027

9.3 Diagnostic Centers

Market Estimates & Forecast, 2020–2027

9.4 Pharmacies

Market Estimates & Forecast, 2020–2027

9.5 Ambulatory Surgical Centers

Market Estimates & Forecast, 2020–2027

9.6 Others

Chapter 10. Global Bone Metastasis Market, by Region

10.1 Introduction

10.2 America

10.2.1 North America

10.2.1.1 U.S.

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K.

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

Chapter 12 Company Profiles

12.1 F. Hoffmann-La Roche Ltd

12.1.1 Company Overview

12.1.2 Type Overview

12.1.3 Financials

12.2.4 Key Developments

12.1.5 SWOT Analysis

12.2 Bayer AG

12.2.1 Company Overview

12.2.2 Type Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Merck & Co., Inc.

12.3.1 Company Overview

12.3.2 Type Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Pfizer Inc.

12.4.1 Company Overview

12.4.2 Type/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Novartis AG

12.5.1 Company Overview

12.5.2 Type Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 Pharmalucence Inc.

12.6.1 Company Overview

12.6.2 Type Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Koninklijke Philips N.V.

12.7.1 Overview

12.7.2 Type Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 GENERAL ELECTRIC

12.8.1 Overview

12.8.2 Type Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 Siemens AG

12.9.1 Overview

12.9.2 Type Overview

12.9.3 Financials

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.10 TOSHIBA CORPORATION

12.10.1 Overview

12.10.2 Type Overview

12.10.3 Financials

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.11 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Bone Metastasis Market

Chapter 14 Appendix

LIST OF TABLES

Table 1 Bone Metastasis Industry Synopsis, 2020–2027

Table 2 Global Bone Metastasis Market Estimates & Forecast, 2020–2027, (USD Million)

Table 3 Global Bone Metastasis Market, by Region, 2020–2027, (USD Million)

Table 4 Global Bone Metastasis Market, by Type, 2020–2027, (USD Million)

Table 5 Global Bone Metastasis Market, by Diagnosis, 2020–2027, (USD Million)

Table 6 Global Bone Metastasis Market, by Treatment, 2020–2027, (USD Million)

Table 7 Global Bone Metastasis Market, by End-User, 2020–2027, (USD Million

Table 8 North America Bone Metastasis Market, by Type, 2020–2027, (USD Million)

Table 9 North America Bone Metastasis Market, by Diagnosis, 2020–2027, (USD Million)

Table 10 North America Bone Metastasis Market, by Treatment, 2020–2027, (USD Million)

Table 11 North America Bone Metastasis Market, by End-User, 2020–2027, (USD Million)

Table 12 U.S. Bone Metastasis Market, by Type, 2020–2027, (USD Million)

Table 13 U.S. Bone Metastasis Market, by Diagnosis, 2020–2027, (USD Million)

Table 14 U.S. Bone Metastasis Market, by Treatment, 2020–2027, (USD Million)

Table 15 U.S. Bone Metastasis Market, by End-User, 2020–2027, (USD Million)

Table 16 Canada Bone Metastasis Market, by Type, 2020–2027, (USD Million)

Table 17 Canada Bone Metastasis Market, by Diagnosis, 2020–2027, (USD Million)

Table 18 Canada Bone Metastasis Market, by Treatment, 2020–2027, (USD Million)

Table 19 Canada Bone Metastasis Market, by End-User, 2020–2027, (USD Million)

Table 20 South America Bone Metastasis Market, by Type, 2020–2027, (USD Million)

Table 21 South America Bone Metastasis Market, by Diagnosis, 2020–2027, (USD Million)

Table 22 South America Bone Metastasis Market, by Treatment, 2020–2027, (USD Million)

Table 23 South America Bone Metastasis Market, by End-User, 2020–2027, (USD Million)

Table 24 Europe Bone Metastasis Market, by Type, 2020–2027, (USD Million)

Table 25 Europe Bone Metastasis Market, by Diagnosis, 2020–2027, (USD Million)

Table 26 Europe Bone Metastasis Market, by Treatment, 2020–2027, (USD Million)

Table 27 Europe Bone Metastasis Market, by End-User, 2020–2027, (USD Million)

Table 28 Western Europe Bone Metastasis Market, by Type, 2020–2027, (USD Million)

Table 29 Western Europe Bone Metastasis Market, by Diagnosis, 2020–2027, (USD Million)

Table 30 Western Europe Bone Metastasis Market, by Treatment, 2020–2027, (USD Million)

Table 31 Western Europe Bone Metastasis Market, by End-User, 2020–2027, (USD Million)

Table 32 Eastern Europe Bone Metastasis Market, by Type, 2020–2027, (USD Million)

Table 33 Eastern Europe Bone Metastasis Market, by Diagnosis, 2020–2027, (USD Million)

Table 34 Eastern Europe Bone Metastasis Market, by Treatment, 2020–2027, (USD Million)

Table 35 Eastern Europe Bone Metastasis Market, by End-User, 2020–2027, (USD Million)

Table 36 Asia Pacific Bone Metastasis Market, by Type, 2020–2027, (USD Million)

Table 37 Asia Pacific Bone Metastasis Market, by Diagnosis, 2020–2027, (USD Million)

Table 38 Asia Pacific Bone Metastasis Market, by Treatment, 2020–2027, (USD Million)

Table 39 Asia Pacific Bone Metastasis Market, by End-User, 2020–2027, (USD Million)

Table 40 The Middle East & Africa Bone Metastasis Market, by Type, 2020–2027, (USD Million)

Table 41 The Middle East & Africa Bone Metastasis Market, by Diagnosis, 2020–2027, (USD Million)

Table 42 The Middle East & Africa Bone Metastasis Market, by Treatment, 2020–2027, (USD Million)

Table 43 The Middle East & Africa Bone Metastasis Market, by End-User, 2020–2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Bone Metastasis Market

Figure 3 Market Dynamics for Global Bone Metastasis Market

Figure 4 Global Bone Metastasis Market Share, by Type 2020

Figure 5 Global Bone Metastasis Market Share, by Diagnosis 2020

Figure 6 Global Bone Metastasis Market Share, by Treatment, 2020

Figure 7 Global Bone Metastasis Market Share, by End-User, 2020

Figure 8 Global Bone Metastasis Market Share, by Region, 2020

Figure 9 North America Bone Metastasis Market Share, by Country, 2020

Figure 10 Europe Bone Metastasis Market Share, by Country, 2020

Figure 11 Asia Pacific Bone Metastasis Market Share, by Country, 2020

Figure 12 The Middle East & Africa Bone Metastasis Market Share, by Country, 2020

Figure 13 Global Bone Metastasis Market: Company Share Analysis, 2020 (%)

Figure 14 F. Hoffmann-La Roche Ltd: Key Financials

Figure 15 F. Hoffmann-La Roche Ltd: Segmental Revenue

Figure 16 F. Hoffmann-La Roche Ltd: Geographical Revenue

Figure 17 Bayer AG: Key Financials

Figure 18 Bayer AG: Segmental Revenue

Figure 19 Bayer AG: Geographical Revenue

Figure 20 Merck & Co., Inc.: Key Financials

Figure 21 Merck & Co., Inc.: Segmental Revenue

Figure 22 Merck & Co., Inc.: Geographical Revenue

Figure 23 Pfizer Inc.: Key Financials

Figure 24 Pfizer Inc.: Segmental Revenue

Figure 25 Pfizer Inc.: Geographical Revenue

Figure 26 Novartis AG: Key Financials

Figure 27 Novartis AG: Segmental Revenue

Figure 28 Novartis AG: Geographical Revenue

Figure 29 Pharmalucence Inc.: Key Financials

Figure 30 Pharmalucence Inc.: Segmental Revenue

Figure 31 Pharmalucence Inc.: Geographical Revenue

Figure 32 Koninklijke Philips N.V.: Key Financials

Figure 33 Koninklijke Philips N.V.: Segmental Revenue

Figure 34 Koninklijke Philips N.V.: Geographical Revenue

Figure 35 GENERAL ELECTRIC: Key Financials

Figure 36 GENERAL ELECTRIC: Segmental Revenue

Figure 37 GENERAL ELECTRIC: Geographical Revenue

Figure 38 Siemens AG: Key Financials

Figure 39 Siemens AG: Segmental Revenue

Figure 40 Siemens AG: Geographical Revenue

Figure 41 TOSHIBA CORPORATION: Key Financials

Figure 42 TOSHIBA CORPORATION: Segmental Revenue

Figure 43 TOSHIBA CORPORATION: Geographical Revenue